Meeting
2020 Gastrointestinal Cancers Symposium
Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens.
Authors
Gabriela Dieguez
Milliman, Inc., New York, NY
Gabriela Dieguez , Andy Surinach , Daniel Mercer , Paul Cockrum , George P. Kim , Pamela Pelizzari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 670)
Abstract #
670
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Real-world safety data and differentiation of second-line (2L) 5-fluorouracil (5-FU) based regimens among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: George P. Kim
Poster
2020 Gastrointestinal Cancers Symposium
Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).
First Author: Eileen Mary O'Reilly
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
First Author: Ramesh K. Ramanathan
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder